{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:21:18Z","timestamp":1790806878120,"version":"4.1.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Roche Polska to support the preparation of this study and the associated manuscript"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"DOI":"10.1186\/s12913-026-14231-9","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T17:17:44Z","timestamp":1771867064000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Multidimensional evaluation of the potential impact of faricimab availability on healthcare system accessibility for retinal disease treatment in Poland"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7196-0015","authenticated-orcid":false,"given":"Micha\u0142","family":"Seweryn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justyna","family":"Kopel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6734-5714","authenticated-orcid":false,"given":"Joanna","family":"Augustynska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Miko\u0142ajewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7152-2613","authenticated-orcid":false,"given":"Mario Damiano","family":"Toro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3321-2723","authenticated-orcid":false,"given":"Robert","family":"Rejdak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,23]]},"reference":[{"issue":"9","key":"14231_CR1","doi-asserted-by":"publisher","first-page":"913","DOI":"10.3390\/jpm14090913","volume":"14","author":"S Nasimi","year":"2024","unstructured":"Nasimi S, Nasimi N, Grauslund J, Vergmann AS, Subhi Y. Real-World Efficacy of Intravitreal Faricimab for Diabetic Macular Edema: A Systematic Review. J Pers Med. 2024;14(9):913. https:\/\/doi.org\/10.3390\/jpm14090913.","journal-title":"J Pers Med"},{"key":"14231_CR2","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12886-025-03953-9","volume":"25","author":"MA Bantounou","year":"2025","unstructured":"Bantounou MA, Elsheikh M, Ijasan A, et al. Real-world experience of intravitreal faricimab injection in previously treated neovascular age-related macular degeneration eyes: a case series. BMC Ophthalmol. 2025;25:117. https:\/\/doi.org\/10.1186\/s12886-025-03953-9.","journal-title":"BMC Ophthalmol"},{"key":"14231_CR3","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1038\/s41433-020-01377-x","volume":"35","author":"AM Joussen","year":"2021","unstructured":"Joussen AM, Ricci F, Paris LP, et al. Angiopoietin\/Tie2 signalling and its role in retinal and choroidal vascular diseases: a review of preclinical data. Eye. 2021;35:1305\u201316. https:\/\/doi.org\/10.1038\/s41433-020-01377-x.","journal-title":"Eye"},{"issue":"8","key":"14231_CR4","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.3390\/cells9081869","volume":"9","author":"M Khan","year":"2020","unstructured":"Khan M, Aziz AA, Shafi NA, Abbas T, Khanani AM. Targeting Angiopoietin in Retinal Vascular Diseases: A Literature Review and Summary of Clinical Trials Involving Faricimab. Cells. 2020;9(8):1869. https:\/\/doi.org\/10.3390\/cells9081869.","journal-title":"Cells"},{"key":"14231_CR5","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1186\/s12886-025-04212-7","volume":"25","author":"X Yufeng","year":"2025","unstructured":"Yufeng X, Ningxi H, Mingzhi S, et al. Real-world outcomes of a loading phase with intravitreal faricimab in refractory Neovascular Age-Related Macular Degeneration (nAMD) patients. BMC Ophthalmol. 2025;25:347. https:\/\/doi.org\/10.1186\/s12886-025-04212-7.","journal-title":"BMC Ophthalmol"},{"issue":"1","key":"14231_CR6","doi-asserted-by":"publisher","first-page":"100111","DOI":"10.1016\/j.xops.2021.100111","volume":"2","author":"N Eter","year":"2021","unstructured":"Eter N, Singh RP, Abreu F, et al. YOSEMITE and RHINE: Phase 3 Randomized Clinical Trials of Faricimab for Diabetic Macular Edema: Study Design and Rationale. Ophthalmol Sci. 2021;2(1):100111. https:\/\/doi.org\/10.1016\/j.xops.2021.100111.","journal-title":"Ophthalmol Sci"},{"issue":"4","key":"14231_CR7","doi-asserted-by":"publisher","first-page":"100076","DOI":"10.1016\/j.xops.2021.100076","volume":"1","author":"AM Khanani","year":"2021","unstructured":"Khanani AM, Guymer RH, Basu K, et al. TENAYA and LUCERNE: Rationale and Design for the Phase 3 Clinical Trials of Faricimab for Neovascular Age-Related Macular Degeneration. Ophthalmol Sci. 2021;1(4):100076. https:\/\/doi.org\/10.1016\/j.xops.2021.100076.","journal-title":"Ophthalmol Sci"},{"issue":"10326","key":"14231_CR8","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S0140-6736(22)00018-6","volume":"399","author":"CC Wykoff","year":"2022","unstructured":"Wykoff CC, Abreu F, Adamis AP, et al. YOSEMITE and RHINE Investigators. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet. 2022;399(10326):741\u201355. https:\/\/doi.org\/10.1016\/S0140-6736(22)00018-6.","journal-title":"Lancet"},{"issue":"10326","key":"14231_CR9","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","volume":"399","author":"JS Heier","year":"2022","unstructured":"Heier JS, Khanani AM, Quezada Ruiz C, et al. TENAYA and LUCERNE Investigators. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399(10326):729\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(22)00010-1.","journal-title":"Lancet"},{"issue":"1","key":"14231_CR10","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s40942-024-00566-0","volume":"10","author":"N Nasimi","year":"2024","unstructured":"Nasimi N, Nasimi S, Grauslund J, Vergmann AS, Subhi Y. Real-world efficacy of intravitreal faricimab for neovascular age-related macular degeneration: a systematic review. Int J Retina Vitreous. 2024;10(1):48. https:\/\/doi.org\/10.1186\/s40942-024-00566-0.","journal-title":"Int J Retina Vitreous"},{"key":"14231_CR11","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40942-024-00525-9","volume":"10","author":"FM Penha","year":"2024","unstructured":"Penha FM, Masud M, Khanani ZA, et al. Review of real-world evidence of dual inhibition of VEGF-A and ANG-2 with faricimab in NAMD and DME. Int J Retin Vitr. 2024;10:5. https:\/\/doi.org\/10.1186\/s40942-024-00525-9.","journal-title":"Int J Retin Vitr"},{"key":"14231_CR12","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.3389\/fphar.2020.01123","volume":"11","author":"A Mela","year":"2020","unstructured":"Mela A, Poniatowski \u0141A, Drop B, et al. Overview and Analysis of the Cost of Drug Programs in Poland: Public Payer Expenditures and Coverage of Cancer and Non-Neoplastic Diseases Related Drug Therapies from 2015\u20132018 Years. Front Pharmacol. 2020;11:1123. https:\/\/doi.org\/10.3389\/fphar.2020.01123.","journal-title":"Front Pharmacol"},{"key":"14231_CR13","unstructured":"National Health Fund. Statistics. Drug Statistics. Drug Programmes. https:\/\/statystyki.nfz.gov.pl\/DrugPrograms Accessed October 30, 2024."},{"key":"14231_CR14","unstructured":"Announcement of the Minister of Health dated September 18. 2024, regarding the list of reimbursed drugs, foodstuffs for special nutritional purposes and medical devices as of October 1, 2024. https:\/\/www.gov.pl\/web\/zdrowie\/obwieszczenie-ministra-zdrowia-z-dnia-18-wrzesnia-2024-r-w-sprawie-wykazu-refundowanych-lekow-srodkow-spozywczych-specjalnego-przeznaczenia-zywieniowego-oraz-wyrobow-medycznych-na-1-pazdziernika-2024-r Accessed Octobe 14, 2024."},{"key":"14231_CR15","unstructured":"National Bank of Poland. Exchange rates. https:\/\/nbp.pl\/en\/statistic-and-financial-reporting\/rates\/ Accessed November 12, 2024."},{"key":"14231_CR16","unstructured":"Statistics Poland, Statistical. Population projection 2023\u20132060. https:\/\/stat.gov.pl\/obszary-tematyczne\/ludnosc\/prognoza-ludnosci\/prognoza-ludnosci-na-lata-2023-2060,11,1.html Accessed October 08, 2024."},{"key":"14231_CR17","unstructured":"Gujski MA, Raciborski F et al. Health Care Institute: Report Eye diseases - a health and social problem and a civilization challenge in the face of an aging population. Warsaw: Instytut Ochrony Zdrowia; 2016. pp. 101\u2013115. ISBN 978-83-944863-2-7."},{"key":"14231_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.vhri.2018.11.002","volume":"19","author":"PJ Mekjavi\u0107","year":"2019","unstructured":"Mekjavi\u0107 PJ, Balciuniene VJ, Ceklic L, et al. The Burden of Macular Diseases in Central and Eastern Europe - Implications for Healthcare Systems. Value Health Reg Issues. 2019;19:1\u20136. https:\/\/doi.org\/10.1016\/j.vhri.2018.11.002.","journal-title":"Value Health Reg Issues"},{"key":"14231_CR19","unstructured":"Retina AMD. Polska Portal, Roche. Report: nAMD - The path from diagnosis to treatment. 2023. Available from: http:\/\/retinaamd.org.pl\/wp-content\/uploads\/2023\/03\/Retina_Raport-FIN.pdf. Accessed October 22, 2024."},{"key":"14231_CR20","unstructured":"Map of health needs. Epidemiological forecast. https:\/\/basiw.mz.gov.pl\/mapy-informacje\/mapa-2022-2026\/analizy\/prognoza-epidemiologiczna\/ Accessed October 22, 2024."},{"key":"14231_CR21","unstructured":"Report No. OT.4221.41.2021. Bevacizumab for the indication: treatment of diabetic macular edema (DME) (ICD10: H36.0). https:\/\/bipold.aotm.gov.pl\/assets\/files\/zlecenia_mz\/2021\/055\/RPT\/55_OT_4221_41_2021_Bewacyzumab_DME_BIP_REOPTR.pdf Accessed October 23, 2024."},{"issue":"3","key":"14231_CR22","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1136\/bjo.2011.204040","volume":"96","author":"DC Minassian","year":"2012","unstructured":"Minassian DC, Owens DR, Reidy A. Prevalence of diabetic macular oedema and related health and social care resource use in England. Br J Ophthalmol. 2012;96(3):345\u20139. https:\/\/doi.org\/10.1136\/bjo.2011.204040.","journal-title":"Br J Ophthalmol"},{"key":"14231_CR23","unstructured":"Map of Health Needs, Drug Programmes. https:\/\/basiw.mz.gov.pl\/en\/maps-of-health-needs\/map-of-health-needs-for-the-period-2022-2026\/analyses\/drug-programmes\/ Accessed October 08, 2024."},{"key":"14231_CR24","unstructured":"NHF Council Resolutions. Resolution No. 29\/2024\/IV dated October 17. 2024, regarding the adoption of the periodic performance report of the National Health Fund for the second quarter of 2024. https:\/\/www.nfz.gov.pl\/zarzadzenia-prezesa\/uchwaly-rady-nfz\/uchwala-nr-292024iv,6679.html Accessed October 25, 2024."},{"key":"14231_CR25","unstructured":"Agency for Health Technology Assessment and Tariff System in Poland. Application for reimbursement of the drug Vabysmo (faricimab) for the indication: Treatment of patients with retinal diseases (ICD-10: H35.3, H36.0). Verification analysis. https:\/\/bip.aotm.gov.pl\/assets\/files\/zlecenia_mz\/2023\/011\/AWA\/011_AWA_OT.423.1.6.2023_Vabysmo_BIP_REOPTR.pdf Accessed October 29, 2024."},{"key":"14231_CR26","unstructured":"NHF Council Resolutions. Resolution No. 5\/2024\/IV dated April 2. 2024, regarding the adoption of the periodic performance report of the National Health Fund for the fourth quarter of 2023. https:\/\/www.nfz.gov.pl\/zarzadzenia-prezesa\/uchwaly-rady-nfz\/uchwala-nr-52024iv,6655.html Accessed October 21, 2024."},{"key":"14231_CR27","unstructured":"Order No. 76\/2024\/DGL of the President of the NHF of 02 August 2024 amending the order on determining terms of concluding and performing contracts for inpatient treatment under drug programmes. National Health Fund. https:\/\/baw.nfz.gov.pl\/NFZ\/document\/43336\/Zarzadzenie-76_2024_DGL Accessed October 25, 2024."},{"key":"14231_CR28","unstructured":"Order No. 175\/2023\/DGL of the President of the NHF of 30 November 2023 order on determining terms of concluding and performing contracts for inpatient treatment under drug programmes. National Health Fund. https:\/\/baw.nfz.gov.pl\/NFZ\/document\/2095\/Zarzadzenie-175_2023_DGL Accessed October 25, 2024."},{"key":"14231_CR29","unstructured":"Information on Concluded Contracts. https:\/\/aplikacje.nfz.gov.pl\/umowy\/Provider\/Search?Branch=01 Accessed October 18, 2024."},{"key":"14231_CR30","unstructured":"World-Class Treatment of Retinal Diseases. Practical Medicine Online Portal. https:\/\/www.mp.pl\/pacjent\/okulistyka\/aktualnosci\/319677,leczenie-chorob-siatkowki-na-swiatowym-poziomie Accessed October 31, 2024."},{"key":"14231_CR31","unstructured":"NHF Council Resolutions. Resolution No. 6\/2020\/III dated March 20. 2020, regarding the adoption of the periodic performance report of the National Health Fund for the fourth quarter of 2019. https:\/\/www.nfz.gov.pl\/zarzadzenia-prezesa\/uchwaly-rady-nfz\/uchwala-nr-62020iii,6527.html Accessed October 21, 2024."},{"key":"14231_CR32","unstructured":"NHF Council Resolutions. Resolution No. 5\/2021\/IV dated March 12. 2021, regarding the adoption of the periodic performance report of the National Health Fund for the fourth quarter of 2020. https:\/\/www.nfz.gov.pl\/zarzadzenia-prezesa\/uchwaly-rady-nfz\/uchwala-nr-52021iv,6555.html Accessed October 21, 2024."},{"key":"14231_CR33","unstructured":"NHF Council Resolutions. Resolution No. 3\/2022\/IV dated March 16. 2022, regarding the adoption of the periodic performance report of the National Health Fund for the fourth quarter of 2021. https:\/\/www.nfz.gov.pl\/zarzadzenia-prezesa\/uchwaly-rady-nfz\/uchwala-nr-32022iv,6592.html Accessed October 21, 2024."},{"key":"14231_CR34","unstructured":"NHF Council Resolutions. Resolution No. 8\/2023\/IV dated March 20. 2024, regarding the adoption of the periodic performance report of the National Health Fund for the fourth quarter of 2022. https:\/\/www.nfz.gov.pl\/zarzadzenia-prezesa\/uchwaly-rady-nfz\/uchwala-nr-82023iv,6627.html Accessed October 21, 2024."},{"issue":"2","key":"14231_CR35","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","volume":"2","author":"WL Wong","year":"2014","unstructured":"Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2):e106\u201316. https:\/\/doi.org\/10.1016\/S2214-109X(13)70145-1.","journal-title":"Lancet Glob Health"},{"key":"14231_CR36","doi-asserted-by":"publisher","unstructured":"Chaudhuri M, Hassan Y, Bakka Vemana PPS, Bellary Pattanashetty MS, Abdin ZU, Siddiqui HF. Age-related macular degeneration: an exponentially emerging imminent threat of visual impairment and irreversible blindness. Cureus 15(5):e39624. https:\/\/doi.org\/10.7759\/cureus.39624","DOI":"10.7759\/cureus.39624"},{"key":"14231_CR37","doi-asserted-by":"publisher","unstructured":"Korobelnik JF, Delcourt C, Creuzot-Garcher C et al. Real-life management of neovascular age-related macular degeneration (nAMD) in France: a nationwide observational study using retrospective claims data. J Med Econ 2021 Jan-Dec;24(1):1087\u201397. https:\/\/doi.org\/10.1080\/13696998.2021.1971416","DOI":"10.1080\/13696998.2021.1971416"},{"key":"14231_CR38","doi-asserted-by":"publisher","first-page":"e56741","DOI":"10.2196\/56741","volume":"10","author":"K Choi","year":"2024","unstructured":"Choi K, Park SJ, Yoon H, et al. Patient-Centered Economic Burden of Diabetic Macular Edema: Retrospective Cohort Study. JMIR Public Health Surveill. 2024;10:e56741. https:\/\/doi.org\/10.2196\/56741.","journal-title":"JMIR Public Health Surveill"},{"issue":"1","key":"14231_CR39","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1177\/11206721211001716","volume":"32","author":"B Pina Mar\u00edn","year":"2022","unstructured":"Pina Mar\u00edn B, Gajate Paniagua NM, G\u00f3mez-Bald\u00f3 L, Gallego-Pinazo R. Burden of disease assessment in patients with neovascular age-related macular degeneration in Spain: Results of the AMD-MANAGE study. Eur J Ophthalmol. 2022;32(1):385\u201394. https:\/\/doi.org\/10.1177\/11206721211001716.","journal-title":"Eur J Ophthalmol"},{"key":"14231_CR40","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1007\/s44411-025-00140-6","volume":"126","author":"L Janco","year":"2025","unstructured":"Janco L, Stefanickova J, Busanyova B, et al. Economic burden of age-related macular degeneration and diabetic macular edema in Slovakia: a cost-of-illness analysis. Bratisl Med J. 2025;126:544\u201351. https:\/\/doi.org\/10.1007\/s44411-025-00140-6.","journal-title":"Bratisl Med J"},{"key":"14231_CR41","doi-asserted-by":"publisher","unstructured":"Seweryn M, Leszczy\u0144ska A, Teper S. Potential in the treatment of neovascular Age-related Macular Degeneration and Diabetic Macular Edema in Poland. -population needs and access to therapy. J Health Policy Outcomes Res. 2024;2. https:\/\/doi.org\/10.7365\/JHPOR.2024.2.1.","DOI":"10.7365\/JHPOR.2024.2.1"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-026-14231-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-026-14231-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-026-14231-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T15:21:12Z","timestamp":1774884072000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12913-026-14231-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,23]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["14231"],"URL":"https:\/\/doi.org\/10.1186\/s12913-026-14231-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7299149\/v1","asserted-by":"object"}]},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,23]]},"assertion":[{"value":"5 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"431"}}